Guardant Health
In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health
A federal judge denied four motions by Guardant but granted four others by the company.
HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders
Premium
New data from a Japanese Phase II study have solidified a path forward for pertuzumab plus trastuzumab in HER2-positive colorectal cancer patients.
Guardant Health Q3 Revenues Up 27 Percent
The company's recorded record revenue for the quarter of $92.6 million, driven by increases in its precision oncology clinical testing business.
Kinnate Biopharma, Guardant Health Partner for Study of BRAF Mutations in Solid Tumors
Preliminary findings indicate that about half of the 6,000 patients with BRAF alteration-positive cancers harbored Class II and III alterations.
GenomeWeb Index up Slightly in August as Guardant Health Leads on Strength of Q2 Earnings
The GenomeWeb Index outperformed the Dow Jones last month, but underperformed the Nasdaq and the Nasdaq Biotechnology Index.
Aug 5, 2021
Guardant Health Q2 Revenues Grow 39 Percent
Jun 22, 2021
May 6, 2021
Guardant Health Q1 Revenues up 17 Percent
Feb 24, 2021
Guardant Health Q4 Revenues Up 25 Percent
Feb 5, 2021